EDNRB and idiopathic pulmonary fibrosis: Endothelin receptor antagonists (ERAs) targeting the endothelin B receptor (EDNRB) exhibit multidimensional therapeutic potential, particularly in idiopathic pulmonary fibrosis (IPF).